Madrigal Pharmaceuticals Inc.
MDGL
NGS
Sector: Healthcare
Industry: Biotechnology
64.77
USD
-0.22
(-0.34%)
Optionable: Yes Market Cap: 1,113 M 90-day average vol: 204,492
Previous close: 64.99 Open: 66.48 Bid: 65.75 Ask: 65.75
52 week range
52.33 105.93
Last updated: Tuesday 4th October 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 12.90 |
PE Ratio (TTM) | -4.20 |
Book Value per Share ($) | 13.74 |
5 Year PE Range | -47.3 , -5.9 |
Returns
7 Day Return | 2.78% | |
1 Month Return | -2.48% | |
3 Month Return | -17.54% | |
1 Year Return | -17.84% | |
3 Year Return | -26.78% | |
5 Year Return | 47.44% | |
YTD Return | -23.57% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 46.45 |
14 Day SMA ($) | 65.53 |
14 Day EMA ($) | 65.62 |
Money Flow Index | 43.98 |
Average True Range | 4.29 |
50 Day SMA ($) | 68.86 |
200 Day SMA ($) | 76.01 |
ADX | 7.96 |
MACD | -1.47 |
Growth
Free Cash Flow QoQ Growth | 15.01% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 23.21% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
MDGL Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 147000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of sales | -738000 | -516000 | -673000 | 0 | 0 | -77000 | -96000 | -112000 | -471000 | -405000 |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling Gen & administrative expense | 12 M | 16 M | 16 M | 805762 | 9 M | 8 M | 15 M | 23 M | 22 M | 37 M |
| Research & development expense | 49 M | 72 M | 68 M | 2 M | 16 M | 24 M | 25 M | 72 M | 185 M | 205 M |
| Operating income | -61 M | -88 M | -84 M | -3 M | -25 M | -32 M | -41 M | -95 M | -207 M | -242 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 0 | 0 | 0 | 0 | 91000 | 350000 | 200000 | 0 | 100000 | 273000 |
| Pre-tax Income (EBT) | -63 M | -90 M | -86 M | -7 M | -26 M | -31 M | -33 M | -84 M | -202 M | -242 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -63 M | -90 M | -86 M | -7 M | -26 M | -31 M | -33 M | -84 M | -202 M | -242 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -63 M | -90 M | -86 M | -7 M | -26 M | -31 M | -33 M | -84 M | -202 M | -242 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -63 M | -90 M | -86 M | -7 M | -26 M | -31 M | -33 M | -84 M | -202 M | -242 M |
| Depreciation | 738000 | 516000 | 673000 | 0 | 0 | 77000 | 96000 | 112000 | 471000 | 405000 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -60 M | -87 M | -83 M | -3 M | -25 M | -32 M | -41 M | -95 M | -206 M | -242 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -37.1 | -44.45 | -30.45 | -18.55 | -5.07 | -2.54 | -2.22 | -5.45 | -13.09 | -14.63 |
| Diluted EPS total | -37.1 | -44.45 | -30.45 | -18.55 | -5.07 | -2.54 | -2.22 | -5.45 | -13.09 | -14.63 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today